Literature DB >> 21725618

miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3.

Chun-Guang Fan1, Chun-Mei Wang, Chuan Tian, Yan Wang, Li Li, Wen-Sheng Sun, Rui-Feng Li, Yu-Gang Liu.   

Abstract

microRNAs (miRNAs) are short, non-coding RNAs with post-transcriptional regulatory functions that participate in diverse biological pathways. miR-122, a liver-specific miRNA, has been found to be down-regulated in hepatocellular carcinoma (HCC) and HCC-derived cell lines. In this study, miR-122 was down-regulated in the hepatitis B virus (HBV)-related HCC cell line HepG2.2.15 compared to HepG2. NDRG3, a member of the N-myc downstream-regulated gene (NDRG) family, was up-regulated in HepG2.2.15 and was identified as a target gene of miR-122. An inverse correlation between the expression of miR-122 and the NDRG3 protein was noted in HBV-related HCC specimens. The transfection of the miR-122 expression vector into the HepG2.2.15 cell line repressed the transcription and expression of NDRG3, which subsequently reversed the malignant phenotype of the cells. The replication of HBV, expression of viral antigens and proliferation of cells were significantly inhibited by restoration of miR-122. The data demonstrate that miR-122 plays an important role in HBV-related hepatocarcinogenesis by targeting NDRG3. Thus, miR-122 and NDRG3 represent key diagnostic markers and potential therapeutic targets for HBV-related HCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21725618     DOI: 10.3892/or.2011.1375

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  47 in total

1.  Hepatitis B virus molecular biology and pathogenesis.

Authors:  R Jason Lamontagne; Sumedha Bagga; Michael J Bouchard
Journal:  Hepatoma Res       Date:  2016-07-01

Review 2.  The role of microRNAs in hepatocyte metabolism and hepatitis B virus replication.

Authors:  Wanyu Deng; Mengji Lu
Journal:  Virol Sin       Date:  2016-12-28       Impact factor: 4.327

Review 3.  miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma.

Authors:  Weiqi Tan; Yang Li; Seng-Gee Lim; Theresa M C Tan
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 4.  Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities.

Authors:  Sebastien Boucle; Leda Bassit; Maryam Ehteshami; Raymond F Schinazi
Journal:  Clin Liver Dis       Date:  2016-08-30       Impact factor: 6.126

Review 5.  Significant biomarkers for the management of hepatocellular carcinoma.

Authors:  Yasuteru Kondo; Osamu Kimura; Tooru Shimosegawa
Journal:  Clin J Gastroenterol       Date:  2015-04-09

6.  MicroRNA-34c targets TGFB-induced factor homeobox 2, represses cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Yan Wang; Chun-Mei Wang; Zhen-Zhong Jiang; Xiao-Jian Yu; Chun-Guang Fan; Fei-Fei Xu; Qing Zhang; L I Li; Rui-Feng Li; Wen-Sheng Sun; Zhen-Hai Zhang; Yu-Gang Liu
Journal:  Oncol Lett       Date:  2015-08-27       Impact factor: 2.967

Review 7.  MiR-122 in hepatic function and liver diseases.

Authors:  Jun Hu; Yaxing Xu; Junli Hao; Saifeng Wang; Changfei Li; Songdong Meng
Journal:  Protein Cell       Date:  2012-05-18       Impact factor: 14.870

Review 8.  Hepatitis B virus and microRNAs: Complex interactions affecting hepatitis B virus replication and hepatitis B virus-associated diseases.

Authors:  Jason Lamontagne; Laura F Steel; Michael J Bouchard
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

9.  Hepatitis B virus mRNA-mediated miR-122 inhibition upregulates PTTG1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion.

Authors:  Changfei Li; Yanzhong Wang; Saifeng Wang; Bo Wu; Junli Hao; Hongxia Fan; Ying Ju; Yuping Ding; Lizhao Chen; Xiaoyu Chu; Wenjun Liu; Xin Ye; Songdong Meng
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

Review 10.  Inflammation and liver tumorigenesis.

Authors:  Beicheng Sun; Michael Karin
Journal:  Front Med       Date:  2013-05-17       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.